Givinostat is a pan-HDAC inhibitor with activity against class I and II histone deacetylases, designed to modulate epigenetic dysregulation and inflammatory signaling in myeloproliferative neoplasms (MPNs). Here, HDAC9 is linked to myeloproliferative neoplasm.